Artiva Biotherapeutics Investor Relations Material

Artiva Biotherapeutics Inc. is a biotechnology company focused on developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer treatment. The company's therapies utilize NK cell technology combined with advanced genetic engineering and proprietary manufacturing processes to enhance the effectiveness of NK cells in targeting cancer cells. Artiva’s therapeutic platforms are designed to address various cancer types, with an emphasis on scalability and accessibility for patients. Its development pipeline covers multiple forms of immunotherapies aimed at both solid tumors and hematologic malignancies. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.